McGuireWoods Guides vVARDIS in $35M Financing Deal

McGuireWoods has successfully advised Swiss dental company vVARDIS in securing a $35 million investment from OrbiMed, a major healthcare investment firm. This substantial funding aims to fuel vVARDIS’ growth and support its global commercial expansion, promising significant developments in non-invasive dental care. 

Renowned for its non-invasive dental products under the Curodont brand, vVARDIS has become a trusted name across thousands of dental clinics in both the United States and the European Union. These products are also featured in lectures at prestigious universities, highlighting their emerging role in early tooth decay management. With the new investment from OrbiMed, vVARDIS is set to further cement its position as a leader in dental innovation. Meanwhile, McGuireWoods, a powerhouse in private equity and healthcare finance transactions, continues to reinforce its expertise, having achieved nationwide recognition for its healthcare, mergers and acquisitions, and private equity capabilities.

This pivotal financing deal marks a significant milestone for vVARDIS, as it embarks on its journey to achieve global expansion and enhance dental care solutions. With McGuireWoods’ strategic guidance and OrbiMed’s investment, the future looks promising for vVARDIS and its innovative dental technologies, potentially transforming dental practices worldwide.

For the latest updates and in-depth insights into the world of Dentistry, including breakthrough treatments, industry trends, and regulatory news, contact Madison Massey today!